Xuanzhu Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	652.23	135.25	142.89	1,125	625.5
Short-Term Investments	-	0.19	0.07	-	-
Trading Asset Securities	-	110.58	306.83	108.11	332.53
Cash & Short-Term Investments	652.23	246.02	449.8	1,233	958.02
Cash Growth	165.12%	-45.30%	-63.53%	28.74%	680.10%
Accounts Receivable	16.04	0.19	-	-	-
Other Receivables	-	13.5	13.53	0.92	0.73
Receivables	16.04	13.69	13.53	0.95	5.81
Inventory	86.52	57.19	62.32	50.94	30.36
Other Current Assets	77.62	52.1	16.79	31.23	10.83
Total Current Assets	832.41	369	542.44	1,316	1,005
Property, Plant & Equipment	115.73	172.15	197.43	153.97	127.07
Other Intangible Assets	337.27	66.86	74.32	71.27	42.69
Long-Term Deferred Charges	320.65	543.7	459.48	270.12	217.22
Other Long-Term Assets	34.29	44.9	47.34	60.12	27.46
Total Assets	1,640	1,197	1,321	1,872	1,419
Accounts Payable	113.57	98.89	69.21	17.25	17.46
Accrued Expenses	32.55	16.59	20.24	35.61	21.56
Current Portion of Leases	0.65	0.83	5.15	-	-
Current Income Taxes Payable	4.53	-	-	0	0.03
Current Unearned Revenue	18.44	19.17	7.25	-	-
Other Current Liabilities	52.05	43.79	41.27	9	28.18
Total Current Liabilities	221.79	179.26	143.13	61.86	67.24
Long-Term Leases	-	0.65	11.92	29.36	0.04
Long-Term Unearned Revenue	34.99	41.63	55.72	-	-
Other Long-Term Liabilities	13.31	18.37	-	-	-
Total Liabilities	270.09	239.91	210.76	91.22	67.28
Common Stock	517.95	450.61	450.61	450.61	1,413
Additional Paid-In Capital	-	1,890	1,890	2,041	664.58
Retained Earnings	-	-2,081	-1,524	-711.3	-725.25
Comprehensive Income & Other	852.31	696.58	293.69	-	0
Shareholders' Equity	1,370	956.71	1,110	1,781	1,352
Total Liabilities & Equity	1,640	1,197	1,321	1,872	1,419
Total Debt	0.65	1.48	17.07	29.36	0.04
Net Cash (Debt)	651.59	244.54	432.73	1,204	957.98
Net Cash Growth	166.45%	-43.49%	-64.06%	25.68%	746.80%
Net Cash Per Share	1.40	0.54	0.96	3.05	-
Filing Date Shares Outstanding	517.95	450.61	450.61	450.61	-
Total Common Shares Outstanding	517.95	450.61	450.61	450.61	-
Working Capital	610.62	189.74	399.31	1,255	937.79
Book Value Per Share	2.65	2.12	2.46	3.95	-
Tangible Book Value	1,033	889.85	1,036	1,709	1,310
Tangible Book Value Per Share	1.99	1.97	2.30	3.79	-
Buildings	-	123.67	114.45	114.92	113.69
Machinery	-	126.8	126.47	85.5	77.8
Construction In Progress	-	1.79	1.64	-	-
Leasehold Improvements	-	3.66	3.66	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.